EBCC-14丨种下希望，迎接乳腺癌患者的春天——会议重磅研究“抢先看”

编者按： 第14届欧洲乳腺癌大会（EBCC-14）即将于2024年3月20日～22日在意大利米兰召开，本次会议聚焦乳腺癌多学科管理中的临床和转化研究新数据，肿瘤瞭望特将会议重磅环节研究进行汇总，以飨读者。如有错误或缺漏，请留言指正。

类型：Award and oral abstract session

▌时间： 3月20日11:00～12:55

▌地点： Silver

3:Intermediate clinical endpoints in early-stage breast cancer:an analysis of individual patient data from the Gruppo Italiano Mammella(GIM)and Mammella Intergruppo trials(MIG)

早期乳腺癌的中间临床终点：Gruppo Italiano Mammella（GIM）和Mammella Intergruppo trials（MIG）的个体患者数据分析

获奖者： Eva Blondeaux，意大利

1:Effects of exercise on fatigue and health-related quality of life(HRQoL)in patients with metastatic breast cancer(mBC)–do the positive effects apply to all?-the multinational randomized controlled PREFERABLE-EFFECT study

运动对转移性乳腺癌（mBC）患者疲劳和健康相关生活质量（HRQoL）的影响——是否对所有患者都有积极影响？多国随机对照PREFERABLE-EFFECT研究结果公布

讲者： Anouk Hiensch，荷兰

2:The effect of pain neuroscience education and behavioural graded activity in breast cancer survivors:a randomised controlled multi-center trial

疼痛神经科学教育和行为分级活动对乳腺癌幸存者的影响：一项随机对照多中心试验

讲者： Astrid Lahousse，比利时

4:Neoadjuvant pembrolizumab or placebo+chemotherapy,followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2−breast cancer:Results from the phase 3 KEYNOTE-756 study

3期KEYNOTE-756研究：新辅助治疗使用帕博利珠单抗联合化疗，随后使用辅助帕博利珠单抗/安慰剂+内分泌治疗早期高危ER+/HER2-乳腺癌

讲者： Javier Cortés，西班牙

1LBA：Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer:final analysis of the ALEXANDRA/IMpassion030 phase 3 trial

辅助化疗使用或不使用atezolizumab治疗Ⅱ期和Ⅲ期三阴性乳腺癌：ALEXANDRA/IMpassion030 3期试验的最终分析

讲者： Heather McArthur，美国

2LBA:Immune subtyping in the Response Predictive Subtypes(RPS)identifies a subset of triple negative(TN)early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy(IO):results from 5 IO arms of the I-SPY2 TRIAL

来自I-SPY2研究5个IO组的结果：反应预测亚型（RPS）中的免疫亚型确定了三阴性（TN）早期乳腺癌患者的一个亚组，对新辅助免疫治疗（IO）的反应可能性非常低。

讲者： Laura J.van't Veer，美国

3LBA:Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer:the experience of the Hellenic Cooperative Oncology Group

晚期乳腺癌患者使用T-DXd和SG的安全性和有效性的真实世界数据：希腊肿瘤合作小组的经验

讲者： Elena Fountzilas，希腊

类型：Award and oral abstract session

▌时间： 3月21日09:30～10:55

▌ 地点： Silver

5:Predictors of long-term adverse quality of life following breast cancer treatment–Insights from the REQUITE cohort study

乳腺癌治疗后长期不良生活质量的预测因素——来自REQUITE队列研究的见解

获奖者： Harkeran Jandu，英国

6:Adjuvant Hypofractionated Whole Breast Irradiation(WBI)Versus Accelerated Partial Breast Irradiation(APBI)in Postmenopausal Women with Early Stage Breast Cancer:5-Years Update of the HYPAB Trial.

HYPAB试验的5年更新：绝经后早期乳腺癌妇女的辅助低分割全乳照射（WBI）与加速部分乳房照射（APBI）

讲者： Davide Franceschini，意大利

7:Pre-operative magnetic resonance guided single dose partial breast irradiation:five-year results of the ABLATIVE trial

术前磁共振引导单剂量部分乳房照射：ABLATIVE研究的5年结果

讲者： Yasmin Civil，荷兰

8:Quality assurance of radiation therapy among patients in the BOOG 2013-08 trial

BOOG 2013-08研究中患者放射治疗的质量保证

讲者： Veerle Wintraecken，荷兰

4LBA:Young boost randomized phase III trial of high vs low boost radiation in young breast cancer patients:10-year results

年轻乳腺癌患者高vs低增强辐射的随机Ⅲ期试验的10年结果

讲者： Sophie Bosma，荷兰

9:Impact of PET/MRI on early breast cancer management:Results from a prospective trial

PET/MRI对早期乳腺癌治疗的影响：一项前瞻性试验的结果

讲者： Rosa Di Micco，意大利

10:Proportion of suboptimal baseline 18F-FDG PET/CT exams in oestrogen positive breast cancer patients according to 18F-FDG uptake in primary tumour–a single center retrospective analysis

一项单中心回顾性分析：根据原发肿瘤中18F-FDG的摄取，检测雌激素阳性乳腺癌患者中基线18F-FDG PET/CT检查不理想的比例

讲者： Melissa Lenaerts，荷兰

11:[18F]FDG whole-body PET-MR including an integrated breast MR protocol for locoregional and distant staging in breast cancer patients-a feasibility study

[18F]FDG全身PET-MR治疗，包括一种用于乳腺癌患者局部和远处分期的综合乳腺MR方案，一项可行性研究

讲者： Thiemo van Nijnatten，荷兰

类型：Oral abstract session

▌时间： 3月22日09:30-11:15

▌地点： Silver

12：Drivers of choice and outcomes of breast-conserving surgery versus mastectomy in breast cancer patients with complete response following neoadjuvant therapy:a retrospective analysis from the EUSOMA database

新辅助治疗后完全缓解的乳腺癌患者选择保乳手术与乳房切除术的驱动因素和结果：来自EUSOMA数据库的回顾性分析

讲者： Federica Martorana，意大利

13：Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands between 1989 and 2021:Time trends and the association with tumour grade

1989年至2021年荷兰乳腺导管原位癌保乳治疗后浸润性复发：时间趋势及与肿瘤分级的关系

讲者： Adri Voogd，荷兰

14：Omission of axillary lymph node dissection in cN2-3 breast cancer patients with an excellent response on primary systemic treatment is safe:4-year oncologic outcome of the MARI protocol

MARI方案的4年肿瘤学结果：未进行腋窝淋巴结清扫的cN2-3乳腺癌患者在初次全身治疗中有良好反应是安全的。

讲者： Annemiek Van Hemert，荷兰

5LBA：Significant higher satisfaction with breast and psychosocial well-being and low complication rate–First report of the 24 months follow-up results from the prospective international mesh-supported pre-pectoral breast reconstruction trial(PRO-Pocket-Trial clinicaltrials.gov:NCT03868514)

乳房和心理健康满意度显著提高，并发症发生率低——前瞻性国际网状研究支持胸前乳房重建试验24个月随访结果的第一份报告（PRO-Pocket-Trial clinicaltrials.gov:NCT03868514）

讲者： Stefan Paepke，德国

6LBA：Minimal vs.maximal invasive axillary management after neoadjuvant systemic therapy in node positive breast cancer:5-year follow-up results of the Dutch MINIMAX registry study

淋巴结阳性乳腺癌新辅助全身治疗后最小与最大侵入腋窝管理：荷兰MINIMAX注册研究的5年随访结果

讲者： Sabine De Wild，荷兰

16：Heterogeneity of ER,PgR,HER2 and Ki67 in multifocal/multicentric breast cancer with a single histotype and same grade:implications for pathologists and oncologists from a large multi-institutional series

ER、PgR、HER2和Ki67在单一组织型和相同级别的多灶/多中心乳腺癌中的异质性：对来自大型多机构系列的病理学家和肿瘤学家的意义

讲者： Cristian Scatena，意大利

17:Integrating spatial and single cell transcriptomics to identify and characterize biologically driven subgroups in invasive lobular carcinoma

整合空间和单细胞转录组学来识别和表征浸润性小叶癌的生物驱动亚群

讲者： Matteo Serra，比利时